EMS is the leading pharmaceutical company in Brazil. Established since 45 years and with 100% national capital, the company has two industrial plants strategically placed in São Bernardo do Campo and Hortolândia, in the state of São Paulo.With a work based on daring, simplicity, excellence and responsibility, the company reached the top of the ranking, but not by chance.The strength of the brand belongs on the constant investments in structure and research, in the continuous expansion of the products line and in the pioneer attitude. As the first Brazilian laboratory to export medicine products to Europe and to produce, in the country, medicine products in fractioned packing and generics, EMS is definitively reinventing the pharmaceutical market.

Manufactures and sells pharmaceuticals

Shanghai Medicilon, Inc. provides outsourced research and development services for pharmaceutical and biotechnology companies through contractual forms. Its business areas include Drug exploration and pharmaceutical research as well as Preclinical studies. Its services include chemistry services such as medical chemistry and synthetic chemistry, drug formulation, biology services such as computational biology and molecular modeling, pharmacology services such as transgenic mouse models and digestive system models, bioanalytical services, pharmacokinetic services, drug safety evaluation, and integrated projects such as chemical drug development and chemical compound druggability assessment. The company was founded by Jin Zhang Chen and Chun Lin Chen on February 2, 2004 and is headquartered in Shanghai, China.

Campbell & Co. is a Canadian private company located in Kamloops, BC, that provides accounting, business advisory and tax preparation service.

Neurim Pharmaceuticals Ltd. is a neuroscience drug discovery and development company. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 by Nava Zisapel and Yehuda Zisapel and is headquartered in Tel-Aviv, Israel.

Lotus Pharmaceutical is a generics pharmaceutical company, founded in 1966 and headquartered in Taiwan. The company became part of the Alvogen Group in 2014, and creates high-value generic products covering CNS, CVS, oncology, female health, and anti-obesity drugs in tablets & hard/softgel capsules, for markets all across the world. The primary focus of Lotus Pharmaceutical is addressing the fast-growing market of oncology. By aligning the company’s internal development and manufacturing capabilities, the company aims to benefit patients, its employees and shareholders alike. The company is proud of its best-in-class R&D and manufacturing platform, across Taiwan and Korea. Furthermore, Lotus Pharmaceutical can reach nearly every global market with its high value pipeline through the company’s direct markets relationship with Alvogen’s commercial units spanning over 30 countries, and through alliances with top-tier pharma companies. Lotus Pharmaceutical produces and promotes a unique portfolio of high quality and difficult-to-make pharmaceutical products, and it is these products which fuels its growth. The company offers high quality and affordable generic medications that help reduce healthcare costs for people across the globe. Lotus Pharmaceutical has more than 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, as well as more than 250 products in the market. The product portfolio of Lotus Pharmaceutical focuses on high growth difficult-to-make generics in the fields of oncology, cardiology, nephrology and central nervous system disease. On top of this, Lotus Pharmaceutical sells and markets a growing portfolio of OTC (over-the-counter) medicines and will be promoting the products of its partner Alvotech – a sister company in the Alvogen Group – and their biosimilar products in Asian markets once approved. The leadership team of is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of its customers. The organisational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.

Shanghai Dean Judicial Appraisal Co., Ltd., established on 2015-11-25, Business scope includes licensed projects:Inspection and testing service;Certification Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:forensic technology,Detection technology,Medical Technology,Technical services in the field of chemical technology,technical consulting,technology development,technology transfer;Legal advice;e-commerce(Not to engage in financial business);electronic product,Computer software and auxiliary equipment sales;Health Management Consulting;Class I medical device,laboratory equipment,Instrumentation,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),electronic product,digital product,building materials,ceramics,Chemical Reagent Sales;Own Equipment Rental;Conference and exhibition services;art(nice)artwork,Collection appraisal service;Security equipment sales;Sales of metal chains and other metal products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Dolorgiet GmbH & Co. KG is a private company headquartered in Sankt Augustin, Germany. The firm manufactures pharmaceutical raw materials. It was founded in 1985. Giuseppe Nardi and Peter Theiss are the current co-CEOs of the company.

Nitto Denko Corp. engages in the manufacture and sale of adhesives, optical films, semiconductors, electronic devices, and consumer products. It operates through the following segments: Industrial Tape, Optronics, Human Life, and Others. The Industrial Tape segment deals with the manufacture and sale of sealing, protective, process, and automotive materials. The Optronics segment offers optical films, printed circuits, and high-precision substrates. The Human Life segment handles the manufacturing services for nucleic acids, nucleic acid synthesis materials, and medical-related materials. The Others segment includes new businesses. The company was founded on October 25, 1918 and is headquartered in Osaka, Japan.

DOLORGIET Beteiligungsgesellschaft mbH is a German private company located in Sankt Augustin that provides investment services.

Beijing Kuer Technology Co., Ltd., established on 2006-02-08, Business scope includes productionIIkind:II-6840In vitro diagnostic reagents;ProductionIIIkind:III-6840In vitro diagnostic reagents;technology development,Technical Services,technical consulting,technology transfer;Import and export,Agent import and export,Technology Import and Export.(Enterprises independently choose operating projects according to law,Carry out business activities;ProductionIIIkind:III-6840In vitro diagnostic reagents,ProductionIIkind:II-6840In vitro diagnostic reagents and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN.

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.